# Alpha Tau Medical Ltd. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Alpha Tau Medical Ltd.). ## Overview Alpha Tau Medical Ltd. is an Israel-based clinical-stage oncology therapeutics company focused on developing and commercializing Alpha DaRT® (Diffusing Alpha-emitters Radiation Therapy), a localized alpha-radiation treatment for solid tumors. The company operates through subsidiaries in the United States, Japan, and Canada and develops its therapy for use in oncology centers and through commercial partners. ## Products & services • Alpha DaRT® localized alpha-radiation therapy for solid tumors • Clinical development of Alpha DaRT® across multiple cancer indications • Manufacturing and supply of Alpha DaRT® treatment components • Commercial partnership support for market access and distribution - **Alpha DaRT® therapy** (70%) — Localized alpha-radiation cancer therapy used to treat solid tumors. - **Clinical development services** (20%) — Research and clinical trial activities supporting new indications and regulatory advancement. - **Manufacturing and supply** (10%) — Production and delivery of therapy components used in treatment administration. - Alpha DaRT® localized alpha-radiation therapy for solid tumors - Clinical development of Alpha DaRT® across multiple cancer indications - Manufacturing and supply of Alpha DaRT® treatment components - Commercial partnership support for market access and distribution ## Customers Alpha Tau’s direct customers and counterparties are oncology treatment providers, clinical investigators, and strategic commercial partners that help bring Alpha DaRT® into clinical and commercial use. The therapy is aimed at patients with solid tumors, while hospitals and treatment centers are the users that procure, administer, or evaluate the product under clinical or partnered programs. - **Oncology hospitals and treatment centers** (primary) — Buy or administer Alpha DaRT® for solid tumor treatment programs and clinical use. - **Strategic commercialization partners** (primary) — Partner with Alpha Tau to commercialize the therapy, handle market access, and scale adoption. - **Clinical research institutions** (secondary) — Run investigator-initiated or company-sponsored studies to validate new indications and outcomes. - **Patients with solid tumors** (primary) — End beneficiaries of the therapy, especially in cancers where localized treatment is being studied. - Hospitals and oncology centers treating solid tumors - Clinical investigators running Alpha DaRT® trials - Commercial partners responsible for U.S. distribution - Patients with difficult-to-treat solid cancers - Healthcare providers seeking localized radiotherapy options ## Geography Alpha Tau is headquartered in Israel and has built an operating footprint that includes the United States, Japan, and Canada through wholly owned subsidiaries. The business is geographically important because clinical development is conducted across multiple markets, while commercialization is expected to depend heavily on the U.S. and other major oncology markets. - Headquartered in Israel, where the technology was developed - U.S. subsidiary supports clinical and commercial activity - Japan subsidiary supports regional development and access - Canada subsidiary extends the company’s North American footprint - Commercial expansion depends on multinational oncology markets ## Strategy Alpha Tau’s strategy is to expand Alpha DaRT® from a single-asset clinical story into a multi-indication oncology platform with both trial execution and commercialization pathways. The company is prioritizing partnership-led market entry, broader clinical validation across tumor types, and manufacturing readiness to support future adoption. - **Expand clinical evidence across tumor indications** (short-term) — Broader data can support regulatory progress and adoption in more oncology settings. - **Commercialize through strategic partnerships** (short-term) — Partners can provide sales execution, market access, and reimbursement expertise. - **Scale manufacturing and supply capability** (medium-term) — Commercial rollout requires reliable production and distribution of treatment components. - Advance multiple tumor indications for Alpha DaRT® - Use partnerships to accelerate U.S. commercialization - Build clinical evidence to support regulatory and adoption pathways - Maintain manufacturing readiness for future demand - Expand global clinical footprint across key oncology markets ## Risks Alpha Tau faces the execution risk typical of clinical-stage oncology companies: clinical trials may fail to confirm efficacy or safety, delaying regulatory and commercial progress. The business also depends on partner execution, manufacturing readiness, and funding support, while oncology adoption can be slow because hospitals must justify new treatment workflows and evidence standards. - **Clinical development failure** [high] — The value of Alpha DaRT® depends on positive safety and efficacy data across indications. - **Commercial partner dependence** [high] — U.S. commercialization and customer engagement may rely on third-party execution. - **Manufacturing and supply chain execution** [medium] — The company must produce and deliver treatment components consistently to support trials and sales. - **Capital-intensive development cycle** [high] — Long clinical timelines and commercialization buildout require sustained funding. - Clinical trial results may not support approval or adoption - Partner dependence can affect sales execution and market access - Manufacturing and supply issues could constrain commercialization - Oncology adoption can be slow and evidence-driven - Funding needs remain important for long development cycles ## Accounting As a clinical-stage biotech, Alpha Tau’s financial reporting is shaped by judgment around research and development spending, share-based compensation, and lease accounting for its operating footprint. The company also discloses material estimates and judgments in its critical accounting policies, while its cash position and long development cycle make balance sheet classification and liquidity-related disclosures important for analysis. - **Research and development expense** — Affects operating loss and comparability across periods - **Share-based compensation** — Affects net loss and diluted share count - **Lease accounting** — Affects balance sheet leverage and operating expense presentation - **Critical estimates and judgments** — Affects consistency of reported results - R&D expense timing affects reported operating losses - Share-based compensation affects personnel cost and equity dilution - Lease accounting impacts right-of-use assets and liabilities - Critical estimates affect valuation and accrual judgments - Cash and deposit balances are important for liquidity analysis --- *Last updated: 2026-09-28T11:57:39.615221+00:00*